Cardiometabolic Disorders

Top Story

Dulaglutide label to reflect new safety, efficacy data in type 2 diabetes, CKD

July 20, 2018
In the Journals

Omega-3 fats show minimal effect on CV health, mortality

July 20, 2018
An increased intake of eicosapentaenoic acid and docosahexaenoic acid from omega-3 fats had minimal or no effect on CV health or mortality, according to a review…

CREDENCE trial stopped early for favorable CKD findings with canagliflozin

July 19, 2018
The steering committee behind the phase 3 CREDENCE clinical trial, evaluating the efficacy and safety of the SGLT2 inhibitor canagliflozin vs. placebo for adults with…
Meeting NewsVideo

VIDEO: Antithrombotic therapy strategies in diabetes 'rapidly evolving'

July 19, 2018
PHILADELPHIA — In this video exclusive, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Heart…
More Headlines »

Understanding and Managing a Complex Dual Dilemma: Diabetes and Dyslipidemia

This activity is supported by an educational grant from Amgen.

Patients with type 2 diabetes have increased cardiovascular risk. Inhibitors of proprotein convertase subtilisin/kexin…
More »
Meeting News

VIDEO: Personalized method of LDL estimation enhances analysis of FOURIER

May 6, 2018
More »
Resource Centers
Heart in Diabetes

Heart in Diabetes


What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia and…
More »